naftopidil has been researched along with Kidney Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arima, K; Ishii, K; Iwamoto, Y; Kanda, H; Kato, M; Sasaki, T; Shiraishi, T; Sugimura, Y; Yamada, Y | 1 |
Gotoh, A; Kanno, T; Nagaya, H; Nishizaki, T | 1 |
2 other study(ies) available for naftopidil and Kidney Neoplasms
Article | Year |
---|---|
Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Animals; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Cell Proliferation; Cells, Cultured; Female; Flow Cytometry; G1 Phase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthalenes; Piperazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2013 |
Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Kidney Neoplasms; Male; Naphthalenes; Piperazines; Prazosin; Prostatic Neoplasms; Urinary Bladder Neoplasms | 2012 |